<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03847779</url>
  </required_header>
  <id_info>
    <org_study_id>UAPV-012019-AVJ</org_study_id>
    <nct_id>NCT03847779</nct_id>
  </id_info>
  <brief_title>Microcirculatory Vasomotor Changes in Type 2 Diabetes With Peripheral Neuropathy</brief_title>
  <acronym>NEUROMICRO</acronym>
  <official_title>Microcirculatory Vasomotor Function in Response to Acute Exercise in Type 2 Diabetes With Peripheral Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Avignon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Avignon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Microcirculatory flow is subject to cyclic changes under the influence of heart rate,
      respiration, myogenic activity, neurogenic factors and endothelial factors. Microcirculatory
      oscillations (vasomotion) contribute significantly to tissue perfusion. Vasomotion analysis
      allowed to discriminate normoglycemic subjects, prediabetic subjects and diabetic subjects.
      Furthermore, changes in vasomotion can precede the emergence of global signs of
      microangiopathy complications in type 2 diabetes. In fact, few studies reported impaired
      vasomotion in type 2 diabetes with peripheral neuropathy. Vasomotion analysis after
      vasodilator (6-min walking test and hyperthermia) and after vasoconstrictor (foot lowering)
      stimulus could be an effective diagnostic tool to sharpen the diagnostic.

      Objectives and Methodology: to study vasomotion at baseline and after exercise, hyperthermia
      and foot lowering within 3 groups of patients: diabetic without peripheral neuropathy,
      diabetic with subclinical peripheral neuropathy and diabetic with peripheral neuropathy and
      one group of sex- age- and body mass index-matched healthy control subjects.

      All the subjects will benefit from a clinical, anthropometric, level of physical activity and
      biological evaluations. Type 2 diabetes participants will benefit from neuropathy evaluation.
      In addition, cutaneous microcirculation (perfusion and vasomotion) by means of Laser Doppler
      Flowmetry and Laser Speckle Imaging will be recorded at rest and after different stimuli
      (exercise, hyperthermia and foot lowering).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All the subjects will benefit from a:

        -  clinical: diabetes duration, treatments

        -  anthropometric: weight, height, BMI

        -  level of physical activity by means of the International Physical Activity Questionary,
           pedometers and the 6 minutes walking test

        -  biological evaluations: glycemia, HbA1C, lipids, high sensitive C-reactive protein,
           fibrinogen, 25(OH)D, creatinine, albumine Type 2 diabetes participants will benefit from
           neuropathy evaluation: sensory tests by means of Semmes-Weinstein monofilament and of
           Nerve Check, amplitude and velocity sural nerve and neuropathic symptom score (NSS) In
           addition, cutaneous microcirculation (perfusion and vasomotion) by means of Laser
           Doppler Flowmetry and Laser Speckle Imaging will be recorded at rest and after different
           stimuli (exercise, hyperthermia and foot lowering).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 4, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in average spectral amplitude of the entire frequency range between baseline and after stimulus</measure>
    <time_frame>Cutaneous blood flow will be recorded during 20 minutes at rest, 10 minutes after foot lowering, 15 minutes after exercise and 20 minutes during hyperthermia</time_frame>
    <description>Spectral analysis by wavelet analysis</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Diabetic Neuropathy Peripheral</condition>
  <condition>Small Vessel Disease of Diabetes Mellitus</condition>
  <condition>Vasodilation</condition>
  <condition>Vasoconstriction</condition>
  <arm_group>
    <arm_group_label>Non-neuropathy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Type 2 diabetic without neuropathy:
Negative findings on Semmes-Weinstein monofilament
Neuropathy symptom score (NSS) &lt;3
Negative findings on Nerve Check and Diabetic Peripheral Neuropathy check.
Interventions by means of Laser Doppler Flowmetry and Laser Speckle Imaging:
&quot;rest&quot; cutaneous microcirculation (perfusion and vasomotion)
&quot;Exercise&quot; cutaneous microcirculation (perfusion and vasomotion)
&quot;Foot lowering&quot; cutaneous microcirculation (perfusion and vasomotion)
&quot;Hyperthermia&quot; cutaneous microcirculation (perfusion and vasomotion)
blood sampling
heart rate variability at rest
pedometer during 4 days
international Physical Activity Questionary
Qualify of Life questionary (EQVOD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neuropathy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Type 2 diabetic with neuropathy
Positive findings on Semmes-Weinstein monofilament
Neuropathy symptom score (NSS) &gt;3
Positive findings on Nerve Check and Diabetic Peripheral Neuropathy check.
Interventions by means of Laser Doppler Flowmetry and Laser Speckle Imaging:
&quot;rest&quot; cutaneous microcirculation (perfusion and vasomotion)
&quot;Exercise&quot; cutaneous microcirculation (perfusion and vasomotion)
&quot;Foot lowering&quot; cutaneous microcirculation (perfusion and vasomotion)
&quot;Hyperthermia&quot; cutaneous microcirculation (perfusion and vasomotion)
blood sampling
heart rate variability at rest
pedometer during 4 days
international Physical Activity Questionary
Qualify of Life questionary (EQVOD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>matched for age, sexe and BMI with diabetic patients.
Interventions by means of Laser Doppler Flowmetry and Laser Speckle Imaging:
&quot;rest&quot; cutaneous microcirculation (perfusion and vasomotion)
&quot;Exercise&quot; cutaneous microcirculation (perfusion and vasomotion)
&quot;Foot lowering&quot; cutaneous microcirculation (perfusion and vasomotion)
&quot;Hyperthermia&quot; cutaneous microcirculation (perfusion and vasomotion)
blood sampling
heart rate variability at rest
international Physical Activity Questionary
Qualify of Life questionary (EQVOD)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>&quot;Rest&quot;</intervention_name>
    <description>Cutaneous perfusion and vasomotion assessment at rest in supoine position</description>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>Neuropathy</arm_group_label>
    <arm_group_label>Non-neuropathy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>&quot;Exercise&quot;</intervention_name>
    <description>Cutaneous perfusion and vasomotion assessment after the 6minute-wlaking test</description>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>Neuropathy</arm_group_label>
    <arm_group_label>Non-neuropathy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>&quot;Foot lowering&quot;</intervention_name>
    <description>Cutaneous perfusion and vasomotion assessment after foot lowering</description>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>Neuropathy</arm_group_label>
    <arm_group_label>Non-neuropathy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>&quot;Hyperthermia&quot;</intervention_name>
    <description>Cutaneous perfusion and vasomotion assessment during hyperthermia</description>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>Neuropathy</arm_group_label>
    <arm_group_label>Non-neuropathy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For diabetic patients, HbA1C &gt;6.5 and diabetes duration &gt;5years

          -  For healthy control no diabetes mellitus, no cardiovascular or renal pathology

        Exclusion Criteria:

          -  nondiabetic neuropathy

          -  on medication known to affect microcirculation

          -  presence of active foot ulcer or wound healing history &lt;3months

          -  inability to walk 6 minutes

          -  alcohol consumption of more than 3 units per day
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Benamo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Avignon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Agn√®s Vinet, PhD</last_name>
    <phone>+33490162930</phone>
    <email>agnes.vinet@univ-avignon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eric Benamo, MD</last_name>
    <phone>+33432753081</phone>
    <email>ebenamo@ch-avignon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Henri Duffaut</name>
      <address>
        <city>Avignon</city>
        <zip>84 000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Benamo, MD</last_name>
      <email>ebenamo@ch-avignon.fr</email>
    </contact>
    <investigator>
      <last_name>Eric Benamo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>January 28, 2019</study_first_submitted>
  <study_first_submitted_qc>February 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2019</study_first_posted>
  <last_update_submitted>February 18, 2019</last_update_submitted>
  <last_update_submitted_qc>February 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vasomotion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

